Keywords: erbitux, fails, meet, progression-free, survival, endpoint, ph

Erbitux fails to meet progression-free survival endpoint in Ph III NSCLC trial

Article | 23 July 2007

Print This

Data from a Phase III open-label examination of Erbitux (cetuximab), in combination with a taxane and carboplatin-based chemotherapy, as a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in